Verena Wiegering, Judith Schick, Meinrad Beer, Benedikt Weissbrich, Stefan Gattenlöhner, Hermann J Girschick, Johannes Liese, Paul G Schlegel, Matthias Eyrich
BACKGROUND: Infection with varicella-zoster virus (VZV) contemporaneously with malignant disease or immunosuppression represents a particular challenge and requires individualized decisions and treatment. Although the increasing use of varicella-vaccines in the general population and rapid initiation of VZV-immunoglobulins and acyclovir in case of exposure has been beneficial for some patients, immunocompromised individuals are still at risk for unfavourable courses. METHODS: In this single center, 6-year analysis we review incidence, hospitalization and complication rates of VZV-infections in our center and compare them to published data...
May 10, 2011: BMC Pediatrics